Lockwood C M, Thiru S, Isaacs J D, Hale G, Waldmann H
Cambridge University Department of Medicine, Addenbrooke's Hospital, UK.
Lancet. 1993 Jun 26;341(8861):1620-2. doi: 10.1016/0140-6736(93)90759-a.
Monoclonal antibodies that target T cells offer an alternative to conventional immunosuppressive drugs in the management of autoimmune disease. "Humanisation" of such monoclonal antibodies makes their clinical use less likely to be prone to the risk of cross-species sensitisation than treatment with rodent antibodies. We describe humanised monoclonal antibody therapy in four patients with severe systemic vasculitis unresponsive to immunosuppressive drugs. Substantial and sustained benefit was seen in three of the four patients, although one of these three patients developed anti-idiotypic antibodies that had to be removed by plasma exchange.
靶向T细胞的单克隆抗体为自身免疫性疾病的治疗提供了一种替代传统免疫抑制药物的方法。与使用啮齿动物抗体治疗相比，此类单克隆抗体的“人源化”使其临床应用不太可能出现跨物种致敏风险。我们描述了4例对免疫抑制药物无反应的严重系统性血管炎患者接受人源化单克隆抗体治疗的情况。4例患者中有3例出现了显著且持续的疗效，尽管这3例患者中有1例产生了抗独特型抗体，必须通过血浆置换清除。
